[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteonecrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteonecrosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,103,137,178,210,233],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100587662","effect-of-hbot-on-femoral-head-avascular-necrosis-avn-100587662",false,"NCT06931301","Effect of HBOT on Femoral Head Avascular Necrosis (AVN)","Effect of Hyperbaric Oxygen Therapy on Osteonecrosis of the Femoral Head When Combined With 3D Navigated Core Decompression With Bone Marrow Aspirate Concentrate","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Diagnosed with femoral head avascular necrosis\n* Enrolled into Yale Avascular Necrosis Program\n* Avascular necrosis lesion is classified as ARCO I or ARCO II by Investigator\n* Surgical Candidate for Core Decompression using 3D image guidance with bone marrow aspirate concentrate\n\nExclusion Criteria:\n\n* Hip has already collapsed due to severe avascular necrosis (ARCO III or ARCO IV)\n* Medical comorbidities that prevent them from being a surgical candidate (example: obesity)\n* Absolute contraindications to HBOT, including severe decompensated cardiac failure or lung disease putting them at high risk for pneumothorax\n* Pregnant\n* Prisoner\n* Does not sign Informed Consent Form","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23],"NA","The primary objective of this study is to determine whether the Hyperbaric Oxygen Therapy (HBOT) conducted under the Marx Protocol improves pain outcomes when combined with core decompression with autologous bone marrow aspirate concentrate to treat patients with femoral head avascular necrosis.",[26,27],"Osteonecrosis","Avascular Necrosis","NOT_YET_RECRUITING","2026-06-30",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":20},"2026-12",{"date":36,"type":20},"2035-04",{"name":38,"class":39},"Yale University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100611443","phase-4-outcomes-from-hyperbaric-oxygen-hbo2-treatment-for-emerging-indications-100611443","NCT07240649","Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications","Emerging Indications for Hyperbaric Oxygen Treatment","Inclusion Criteria:\n\n* Patients referred for HBOT with an emerging indication\n\nExclusion Criteria:\n\n* Contraindication to hyperbaric oxygen treatment (untreated seizures, pneumothorax, significant pulmonary airspace pathology that might lead to pulmonary barotrauma, unmanageable confinement anxiety, chronic obstructive pulmonary disease with CO2 retention)\n* Pregnant persons",{"count":49,"type":20},100,[51],"PHASE4","This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.",[54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,26,86,87,88,89,90,91,92,93],"Post-COVID-19 Condition","Ulcerative Colitis","Crohn Disease","Calciphylaxis","Frostbite","Acute COVID-19","Pyoderma Gangrenosum","Pterygium","Hypospadias","Head Trauma","Pneumatosis Intestinalis","Ischemic Bowel","Raynaud Syndrome","Malignant Otitis Externa","Nonarteritic Anterior Ischemic Optic Neuropathy","Central Retinal Vein Occlusion","Femoral Head Necrosis","Invasive Fungal Infection","Chronic Anal Fissure","Vasculitic Ulcer","Graft-vs-Host Disease","Decubitus Ulcer","Greater Trochanteric Pain Syndrome","Rectovaginal Fistula","Pouchitis","Tinnitus","Clostridium Enterocolitis","Branch Retinal Artery Occlusion","Axonotmesis","Multiple Sclerosis","Inclusion Body Myositis","Epidermolysis Bullosa (EB)","Ulcer Ischemic","Avascular Necrosis of Bone","Prosthesis Related Infections","Facial Filler Injections","Cystitis Chronic","Ligament Injury","Anastomosis, Leaking","Cartilage Injury","2026-05-01",{"date":96,"type":32},"2026-05-05",{"date":98,"type":20},"2026-08",{"date":100,"type":20},"2035-12",{"name":102,"class":39},"Jay C. Buckey Jr.",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":40},"100517368","phase-2-alendronate-for-osteonecrosis-in-adults-with-sickle-cell-disease-100517368","NCT06016634","Alendronate for Osteonecrosis in Adults With Sickle Cell Disease","A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease","Inclusion Criteria:\n\n* Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)\n* Ability to provide written informed consent\n* Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner\n* Negative urine pregnancy test for anyone of childbearing potential at study entry\n\nExclusion Criteria:\n\n* Pregnant women\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Hospitalizations (for any cause) within 2 weeks of study entry","80 Years",{"count":112,"type":20},30,[114],"PHASE2","A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis",[117,118,26,119,27],"Sickle Cell Disease","Sickle Cell Anemia","Ischemic Necrosis",[121,122,123,124,125,126],"sickle cell disease","sickle cell anemia","osteonecrosis of the femoral head","hip osteonecrosis","ischemic necrosis of the femur","avascular necrosis of the femur","RECRUITING","2026-04-08",{"date":130,"type":32},"2026-04-13",{"date":132,"type":32},"2026-03-09",{"date":134,"type":20},"2027-12-31",{"name":136,"class":39},"University of California, Davis",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":147,"briefSummary":148,"conditions":149,"keywords":155,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":40},"100579345","early-feasibility-study-of-cartilage-defect-repair-100579345","NCT06823089","Early Feasibility Study of Cartilage Defect Repair","Inclusion Criteria:\n\n1. At least 14 years of age to no older than 64 years of age Subjects 14-21 years of age must have radiographic evidence of epiphyseal closure in the hip joint\n2. BMI \\\u003C 35\n3. Failed at least 6 weeks of conservative treatment (e.g., anti-inflammatory pain medications, physical therapy, injections)\n4. Duration of symptoms consistent with intra-articular disease (i.e., groin, lateral and\u002For posterior hip pain) that have persisted for at least 3 months)\n5. Loss of articular cartilage integrity (\\~1 - 6 cm\\^2 in area) on the femoral head (confirmed by MRI), without an opposing lesion, that can be treated with a single ReNew Hip Implant\n6. Radiographic assessment with joint space width \\> 2 mm (verified by x-ray)\n7. Meets an acceptable preoperative medical clearance and is free of conditions that would pose excessive operative risk, in the opinion of the investigator\n8. Given consent to participate in the study\n9. Able to understand the purpose of the study, his\u002Fher role, and is available for follow-up for the duration of the study:\n\n   1. Subject has signed an IRB (Institutional Review Board) approved Informed Consent Form agreeing to participate in the extension study after the nature, scope, and possible consequences of the study have been explained in an understandable form\n   2. Subject is able to fully understand the purpose of the study, his\u002Fher role as a participant in the study, and plans to be available through five years post-operative follow-up\n\nExclusion Criteria:\n\n1. Current users of nicotine in any form (e.g., cigarettes, e- cigarettes\u002Fvaping, chewing tobacco, nicotine patches, gum, lozenges), or individuals who have discontinued nicotine use less than 30 days prior to screening.\n2. Type 1 or Type 2 Diabetes\n3. Systemic steroid use in the 3 months prior to screening\n4. Coxa plana, coxa magna, or proximal femoral focal deficiency on the femoral head that would result in implant mismatch of the femoral head contour\n5. Any acute or chronic condition that would limit the ability of the patient to participate in the study (e.g., COPD, congestive heart failure),\n6. Bleeding disorders\n7. Current cancer (with the exception of non-melanoma skin cancer)\n8. Pregnancy or planning to become pregnant during the study period\n9. Active infection or sepsis\n10. History of local hip infection\n11. Known metastatic or neoplastic disease\n12. Conditions that may interfere with implant survival or outcomes (e.g., severe dysplasia)\n13. Life expectancy less than 2 years\n14. Intra-articular therapy within 3 months of enrollment\n15. Inadequate bone stock (as determined by SCORE or MORES assessment) to support the device\n16. Femoral head is:\n\n    1. outside of the 46 - 56 mm range in either anteroposterior diameter or lateral diameters or\n    2. an aspherical head deformity that results in contour mismatch of 16a\n17. Moderate to severe renal insufficiency\n18. Emotional or neurological condition that would preempt ability or willingness to participate in the study\n19. Above the knee amputation of the contralateral or ipsilateral leg\n20. Known allergies to the components of the device (polycaprolactone)\n21. Is a prisoner","14 Years","64 Years",{"count":146,"type":20},15,[23],"Any patient aged 14 or older up to 64 years of age with hip disease, resulting in loss of articular cartilage integrity on the femoral head (e.g., femoroacetabular impingement or other structural deformity), has failed conservative care, and is a candidate for surgical intervention to treat.",[150,151,26,152,153,154],"Osteoarthritis, Hip","Femoroacetabular Impingement","Legg-Calvé-Perthes Disease","Osteochondral Lesion","Hip Dysplasia",[156,157,158,159,160,161,162,163,164,165,166,167,168],"articular cartilage","hip resurfacing","residual Perthes disease","post-Perthes deformity","femoral head deformity","secondary hip osteoarthritis","hip preservation surgery","adolescent hip deformity","adult hip deformity","avascular necrosis of femoral head","early-stage avascular necrosis","Perthes sequelae","traumatic femoral head lesion","2026-02-12",{"date":171,"type":32},"2026-02-17",{"date":173,"type":32},"2025-11-06",{"date":175,"type":20},"2031-10",{"name":177,"class":39},"Cytex Therapeutics, Inc.",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":185,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":209},"100485642","exactech-shoulder-post-market-clinical-follow-up-study-100485642","NCT05603728","Exactech Shoulder Post Market Clinical Follow-up Study","An Open Label, Multi-Center, Retrospective and Prospective Evaluation of Shoulder Arthroplasty Clinical and Radiographic Outcomes","Inclusion Criteria:\n\n* Patient is indicated for shoulder arthroplasty (or has previously undergone shoulder arthroplasty)\n* Patient is skeletelly mature\n* Patient is expected to survive at least 2 years beyond surgery\n* Patient is willing to participate by complying with pre- and postoperative visit requirements\n* Patient is willing and able to read and sign a study informed consent form\n\nExclusion Criteria:\n\n* Osteomyelitis of the proximal humerus or scapula; if a systemic infection or a secondary remote infection is suspected or confirmed, implantation should be delayed until infection is resolved\n* Inadequate or malformed bone that precludes adequate support or fixation of the prosthesis\n* Medial humeral bone loss resulting in compromised humeral stem fixation\n* Proximal humeral bone loss extending distal to the surgical neck where there is compromised humeral stem fixation\n* Neuromuscular disorders that do not allow control of the joint\n* Significant injury to the brachial plexus\n* Non-functional deltoid muscles\n* Patient's age, weight, or activity level would cause the surgeon to expect early failure of the system\n* The patient is unwilling or unable to comply with the post-operative care instructions\n* Alcohol, drug, or other subtance abuse\n* Any disease state that could adversaly affect the function or longevity of the implant\n* Patient is pregnant\n* Patient is a prisoner\n* Patient is contraindicated for the surgery\n* Revision cases in which a stemmed humeral component was used (Stemless Shoulder System)\n* Metal allergy or sensitivity to the implants materials (Stemless Shoulder System)\n* Acute fracture of the proximal humerus and displacement of the tuberosities, displaced three or four part fractures of the proximal humerus (hemi-arthroplasty), or acture fracture of the proximal humerus with failure of the glenohumeral joint (total anatomic shoulder arthroplasty) (Stemless Shoulder System)\n* Acute fracture of the proximal humerus in combination with degenerative diseases of the glenohumeral joint and a grossly deficient, irreparable rotator cuff resulting in superior migration of the humeral head (reverse total shoulder arthroplasty) (Stemless Shoulder System)","21 Years",{"count":187,"type":20},20000,"OBSERVATIONAL","The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time. This study will follow subjects long-term for a minimum of 10-years, without an early-term restriction on the amount of time they will be followed.",[191,26,192,193,194,195,196,197,198],"Osteo Arthritis Shoulders","Rotator Cuff Tears","Rotator Cuff Tear Arthropathy","Ankylosing Spondylitis","Post-traumatic Osteoarthritis","Rheumatoid Arthritis","Fracture","Infections","2025-12-09",{"date":201,"type":32},"2025-12-15",{"date":203,"type":32},"2007-07-19",{"date":205,"type":20},"2031-12-31",{"name":207,"class":208},"Exactech","INDUSTRY",38,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":217,"targetDuration":219,"studyType":188,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":229,"leadSponsor":231,"locationsCount":40},"100495703","promis-evaluation-study-100495703","NCT05734651","PROMIS Evaluation Study","Prospective Evaluation of the PROMIS Stem for Primary Total Hip Arthroplasty","Inclusion Criteria:\n\n* Primary total hip arthroplasty with the PROMIS stem\n\nExclusion Criteria:\n\n* n\u002Fa",{"count":218,"type":20},200,"20 Years","A total of 250 total hip arthroplasties (THA) are performed at the Bezirkskrankenhaus St. Johann. In a majority of those, implants from the company Falcon Medical (Austria) are used. Those implants are undergoing constant development and improvement. To guarantee their clinical performance, this clinical study is evaluating safety and efficacy of all implants produced by Falcon Medical.\n\nThe purpose of this study is to evaluate the effcacy and safety of implants produced and distributed by Falcon Medical. All patients with primary THA and usage of a Falcon Medical implant are included. The outcome measures include intra-operative complications, early post-operative complications, revision for any cause and patient reported outcome (WOMAC questionnaire). All data is prospectively collected in a standardized fashion.",[222,150,223,26,224],"Hip Arthropathy","Perthes Disease","Femoral Neck Fractures","2023-02-09",{"date":227,"type":32},"2023-02-21",{"date":225,"type":32},{"date":230,"type":20},"2042-02-09",{"name":232,"class":39},"Bezirkskrankenhaus St. Johann in Tirol",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":240,"targetDuration":242,"studyType":188,"phases":4,"briefSummary":243,"conditions":244,"keywords":247,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":40},"100259802","prospective-registry-of-prosthodontic-rehabilitation-in-oncology-patients-undergoing-jaw-reconstruction-100259802","NCT02661139","Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction","O-BRIDGE","Inclusion Criteria:\n\n* Patients of all ages\n* Patients of all genders\n* Patients with a histologically or clinically confirmed diagnosis of ORN, MRONJ, as classified by Ruggiero et al. (Ruggiero, et al., 2014) or carcinoma located in the oral cavity and jawbone, requiring segmental or total jaw resection\n* Patients eligible for jaw and oral cavity reconstruction combined with immediate\u002Fdelayed implant loading for fixed prosthetic rehabilitation\n* Patients not eligible for conventional removable prosthetic rehabilitation\n\nExclusion Criteria:\n\n* Patients with a clinically confirmed diagnosis of osteonecrosis not related to an oncological diagnosis or treatment\n* Patients with medical contraindications for jaw reconstruction combined with immediate implant loading for fixed prosthetic rehabilitation\n* Patients eligible for conventional removable prosthetic rehabilitation",{"count":241,"type":20},55,"5 Years","The investigators aim to develop a prospective database in which patient demographics, surgical, dental, prosthetic and QOL parameters collected during consecutive visits within the framework of routine practice, are being registered for each oncological patient eligible for (immediate\u002Fdelayed) fixed prosthodontic rehabilitation at time of oral cavity reconstruction",[245,26,246],"Head and Neck Cancer","Osteoradionecrosis",[248,249,250,251,252],"bisphosphonates","jaw reconstruction","prosthetic rehabilitation","quality of life","monoclonal antibodies' targeted therapy","2022-02-23",{"date":255,"type":32},"2022-02-28",{"date":257,"type":4},"2013-06",{"date":259,"type":20},"2027-12",{"name":261,"class":39},"AZ Sint-Jan AV"]